GLP-1 Weight-Loss Drugs Linked to Slowed Cancer Spread

Recent research indicates that glucagon-like peptide-1 (GLP-1) weight-loss drugs may help reduce the progression of certain obesity-related cancers. This research, conducted by Cleveland Clinic, will be presented at an upcoming medical conference.

Study Overview

The study included 12,112 patients diagnosed with various obesity-linked cancers, ranging from stage 1 to stage 3. Researchers explored the effects of GLP-1 drugs such as semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, and pramlintide. These were compared to a different class of diabetes medications known as DPP-4 inhibitors, or “gliptins.”

Impact on Cancer Progression

Patients on GLP-1 medications exhibited lower progression rates to stage 4 disease compared to those taking gliptins. The most significant reductions were observed in:

• Non-small cell lung cancer: 50% reduction
• Breast cancer: 43% reduction
• Colorectal cancer: 31% reduction
• Liver cancer: 38% reduction

“Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,” explained Dr. Mark David Orland of the Taussig Cancer Institute at Cleveland Clinic.

Other Findings

While three other cancers—prostate, pancreatic, and kidney—also showed lower rates of spread among GLP-1 users, these results were not statistically significant. Notably, tumors with elevated levels of GLP-1 receptors were linked to improved survival outcomes. Patients with more GLP-1 receptors in their tumors were about one-third less likely to die during the study period.

Study Limitations and Future Research

The research had several limitations as it was a retrospective and observational study, not a randomized clinical trial. This means it could not definitively prove that GLP-1 drugs prevent cancer progression. Other variables, such as the patient’s health status, weight loss, and metabolic improvements, might have impacted the results.

Further randomized clinical trials are essential to verify these preliminary findings and to explore how GLP-1 drugs can control cancer progression. More research is needed to understand the mechanisms by which GLP-1 pathways affect cancer growth or spread.